Journal article
Efficacy of docetaxel-based chemotherapy following ketoconazole in metastatic castration-resistant prostate cancer: Implications for prior therapy in clinical trials
Abstract
OBJECTIVES: Abiraterone acetate (AA) is a CYP17 inhibitor of androgen synthesis approved for use following docetaxel for metastatic castration-resistant prostate cancer (mCRPC); evaluation in the pre-docetaxel setting is ongoing. Given that the reported efficacy of AA is lower following docetaxel vs. pre-docetaxel, the potential exists for cross resistance given docetaxel's partly androgen receptor targeting activity. The efficacy of docetaxel …
Authors
Pond GR; Armstrong AJ; Galsky MD; Wood BA; Leopold L; Sonpavde
Journal
Urologic Oncology Seminars and Original Investigations, Vol. 31, No. 8, pp. 1457–1463
Publisher
Elsevier
Publication Date
11 2013
DOI
10.1016/j.urolonc.2012.02.008
ISSN
1078-1439
Associated Experts
Fields of Research (FoR)
Medical Subject Headings (MeSH)
AgedAntineoplastic Combined Chemotherapy ProtocolsDisease-Free SurvivalDocetaxelGossypolHumansKetoconazoleMaleMiddle AgedNeoplasm MetastasisOutcome Assessment, Health CarePrednisoneProportional Hazards ModelsProspective StudiesProstate-Specific AntigenProstatic Neoplasms, Castration-ResistantRetrospective StudiesTaxoids